BUSINESS● LOW3h ago · Sep 15, 2026, 8:54 PM
Novartis' Lutathera now facing generic competition from Cirium's Bexlutry
Seeking Alpha Tech · global
Novartis' drug Lutathera is now facing generic competition from Cirium's Bexlutry, indicating a shift in the pharmaceutical market for this specific treatment. This could impact Novartis' market share and revenue.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS12m agoSoutheast Asian buyers emerge as top non-local investors in Hong Kong commercial propertySouth China Morning PostBUSINESS24m agoCarney sells Canada to global investors but says US ties still keySouth China Morning Post